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Abstract 
Background: ANGPTL8 also called betatrophin is a regulator of lipid metabolism through its interaction with 
ANGPTL3. It has also been suggested to play a role in insulin resistance and beta‑cell proliferation. Based on its 
function, we hypothesized that ANGPTL8 will play a role in Metabolic Syndrome (MetS). To test this hypothesis we 
designed this study to measure ANGPTL8 level in subjects with MetS as well as its association with high sensitivity 
C‑reactive protein (HsCRP) level in humans.
Methods: ANGPTL8 level was measured using ELISA in subjects with MetS as well as their controls, a total of 1735 
subjects were enrolled. HsCRP was also measured and its association with ANGPTL8 was examined.
Results: ANGPTL8 level was higher in subjects with MetS 1140.6 (171.9–11736.1) pg/mL compared to 710.5 
(59.5–11597.2) pg/mL in the controls. Higher levels of ANGPTL8 were also observed with the sequential increase 
in the number of MetS components (p value = <0.0001). ANGPTL8 showed strong positive correlation with HsCRP 
(r = 0.15, p value = <0.0001). Stratifying the population into tertiles according to the level of HsCRP showed 
increased ANGPTL8 level at higher tertiles of HsCRP in the overall population (p value = <0.0001).A similar trend 
was also observed in MetS and non‑MetS subjects as well as in non‑obese and obese subjects. Finally, multiple 
logistic regression models adjusted for age, gender, ethnicity and HsCRP level showed that subjects in the highest 
tertiles of ANGPTL8 had higher odds of having MetS (odd ratio [OR] = 2.3, 95 % confidence interval [CI] = (1.6–3.1), p 
value <0.0001.
Conclusion: In this study we showed that ANGPTL8 is increased in subjects with MetS and it was significantly associ‑
ated with HsCRP levels in different subgroups highlighting its potential role in metabolic and inflammatory pathways.
© 2016 Abu‑Farha et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
MetS is a cluster of metabolic risk factors that are asso-
ciated with an increased risk of metabolic related dis-
eases such as cardiovascular diseases (CVD) and type 
2 diabetes (T2D) [1–3]. In a meta-analysis study, MetS 
was shown to cause a twofold increase in cardiovascular 
outcomes and a 1.5-fold increase in all-cause mortality 
[1]. Central obesity, dyslipidemia, elevated blood pres-
sure, elevated fasting glucose and insulin resistance are 
the most pivotal components of MetS [4–7]. MetS is also 
characterized by a chronic low grade inflammation state 
which can explain the increased CVD and T2D risk [8]. 
HsCRP is a proinflammatory protein that is produced by 
the liver in response to cytokine production due to acute 
inflammation. HsCRP is a marker of low grade inflam-
mation which was shown in many studies to be higher 
in subjects with MetS. It was also shown that increased 
level of HsCRP is associated with increased risk of CVD 
and T2D [9–11]. Furthermore, it was shown that adding 
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HsCRP to the definition of MetS will increase its predic-
tive power of CVD and T2D [9–12].
ANGPTL8 is another liver produced protein that 
has been recently given increased attention due to its 
role in lipid metabolism and insulin resistance [13–15]. 
ANGPTL8 showed high level of expression in white, 
brown adipose tissues as well as the liver [14, 15]. It was 
suggested that ANGPTL8 is an atypical ANGTPL protein 
which closely interacts and regulates ANGTPL3 affecting 
levels of TG, HDL-C and LDL-C [13, 15–17]. ANGPTL8 
or betatrophin- as called by Yi et al. has been suggested 
to increase beta-cell proliferation and beta-cell mass in 
insulin resistance mouse model [18]. However, recent 
data challenged the findings of Yi et al. and it was shown 
that ANGPTL8 does not play a role in beta-cell prolifera-
tion under insulin resistance conditions [19, 20].
We have recently showed that ANGPTL8 is increased 
in T2D and was associated with increased C-peptide 
level in non-diabetic subjects [21, 22]. However, the role 
of ANGPTL8 in metabolic syndrome as well as its asso-
ciation with inflammatory markers like HsCRP has not 
yet been well studied. As a result, we designed this popu-
lation study to look at the association between HsCRP 
and ANGPTL8 and their relationship with MetS and its 
components.
Research design and methods
Study participants and anthropometric and physical 
measurements and ethics, consent and permissions
This study was performed on 1735 adult (>18 years old) 
South Asians (Indians and Pakistanis) and Arabs living 
in Kuwait as previously described [21–23]. Briefly, the 
samples have been continuously collected randomly from 
multi-ethnic subjects living in Kuwait. Subjects younger 
than 18 and older than 65 or suffering from any kind of 
infection were excluded. The non-diabetic subjects were 
then selected as subjects without disease and not taking 
any medications. Subjects with cardiovascular diseases 
were excluded from the study. No treatment was received 
before sampling. The study conformed to the principles 
outlined in the Declaration of Helsinki and in accordance 
with the approved guidelines. The study was approved by 
the Ethical Review Committee at Dasman Diabetes Insti-
tute (DDI). An informed written consent was obtained 
from all the participants before their enrolment in the 
study.
Physical and anthropometric measurements included 
body weight, height, waist circumference (WC). These 
were measured as described previously [21–23]; height 
and weight were measured, with participants wearing 
light indoor clothing and barefooted, using calibrated 
portable electronic weighing scales and portable inflex-
ible height measuring bars. WC was measured using 
constant tension tape at the end of a normal exhalation, 
with arms relaxed at the sides, at the highest point of the 
iliac crest and at the mid-axillary line. BMI was calcu-
lated using the standard BMI formula: body weight (in 
kilograms) divided by height (in meters squared).
Laboratory measurements
Blood samples were obtained after fasting overnight 
for at least 10 h and analyzed for Fasting Blood Glucose 
(FBG), hemoglobin A1c (HbA1c), fasting insulin, and 
lipid profiles that included triglyceride (TG), Total cho-
lesterol (TC), low density lipoprotein (LDL) and high 
density lipoprotein (HDL). Glucose and lipid profiles 
were measured on the Siemens Dimension RXL chem-
istry analyzer (Diamond Diagnostics, Holliston, MA). 
HbA1c was determined using the VariantTM device 
(BioRad, Hercules, CA) as described earlier [21–23].
Diabetes and MetS diagnosis and guidelines
The current recommendations and updated guidelines 
for the definition, diagnosis and classification of T2D, 
published by the International Diabetes Federation (IDF), 
have been used. Diabetes was defined by fasting plasma 
glucose ≥ 7 mmol/l, under treatment, or self-reported of 
previously diagnosed T2D [24]. Impaired fasting glucose 
(IFG) was defined by fasting blood glucose values ≥ 5.6 
and  <7  mmol/L. The current recommendations and 
updated guidelines for the definition, diagnosis and clas-
sification of MetS, published by the International Dia-
betes Federation (IDF), were used. MetS was defined by 
abdominal obesity and at least two of the following: fast-
ing blood glucose values  ≥  5.6  mmol/L, hypertension 
was defined as BP ≥ 130/85 mmHg, under treatment, or 
a self-report of previously diagnosed hypertension [25] 
Hypertriglyceridemia as  ≥  1.7  mmol/L and low HDL 
cholesterol as  <1.03  mmol/L in men and  <1.29  mmol/L 
in women. BMI between 18.5 and 24.9 was considered 
normal, 25–29.9, overweight, and equal to or higher than 
30, was considered obese. Cutoffs for central obesity were 
adopted from IDF; they were defined based on race and 
gender. In Arabs WC ≥  94  cm in men and  ≥80  cm in 
women was used, whereas for South Asians central obe-
sity cutoffs were WC ≥ 90 cm for men and WC ≥ 80 cm 
for women.
ANGPTL8 and HsCRP ELISA level
To measure metabolic markers, blood was drawn into 
EDTA tubes. Plasma was obtained after centrifugation, 
aliquoted and then stored at −80  °C. ANGPTL8 con-
centration was determined using ELISA (Wuhan EIAAB 
Science, China) as previously described [21, 22]. Optimal 
dilution was found to be between 1:10–1:40 and a dilu-
tion of 1:25 was used. Inter-assay coefficients of variation 
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were 1.2 to 3.8  % while the intra-assay coefficients of 
variation were 6.8 to 10.2  %. HsCRP secreted level was 
measured using ELISA kit (Biovendor, USA) and meas-
ured according to manufacturer’s protocol as previously 
described [23].
Statistical analysis
Normality tests were run to assess data distribution. 
Comparisons between subjects with MetS and without 
MetS were made by Student’s t test or Wilcoxon test 
for non-parametric analyses in variables with non-nor-
mal distribution. To assess the difference in categori-
cal variables between subjects with and without MetS, 
a Chi Squared test was used. Spearman’s correlation 
coefficients were estimated to determine associations 
between ANGPTL8, HsCRP and anthropometric meas-
urements and biochemical variables. Subjects were clas-
sified into tertiles based on their circulating betatrophin 
levels in the overall population. ANGPTL8 tertile val-
ues are T1 ≤ 689.52.4 pg/mL, T2 689.52 ≤ 1302.63 pg/
mL, T3  >  1302.63  pg/mL. Tertile values of HsCRP are 
expressed as T1 (<1.39), T2 (1.39–4.07), and T3 (>4.07).
A multivariable logistic regression analysis was per-
formed to estimate odds ratios (ORs) adjusted for covari-
ates and to assess the predictive effect of betatrophin 
on risk for T2D. All data are reported as Mean ± stand-
ard deviation (SD) and range, unless stated otherwise. 
Research Electronic Data Capture (REDCap) was used 
for data collections and data management. All statistical 
assessments were two-sided and considered to be sig-
nificant when P value <0.05. All analyses were performed 
using SAS (version 9.2; SAS Institute, Cary, NC).
Results
Population characteristics are outlined in Table  1. Our 
population was made of 1735 subjects, 724 of which 
were non-MetS and 1011 were MetS subjects. The aver-
age age of participants was 41.1  ±  10.6 for non-MetS 
subjects and 49.0  ±  10.9 for subjects with MetS. Sub-
jects with MetS had a significantly higher BMI, waist/hip 
ratio, systolic and diastolic blood pressure, FBG, HBA1c, 
insulin, HOMA-IR, TG, TC, HDL, and LDL (p  <  0.05). 
ANGPTL8 showed close to twofold increase in sub-
jects with MetS relative to non-MetS subjects 1140.6 
(171.9–11736.1) pg/mL vs. 710.5 (59.5–11597.2) pg/mL 
respectively (P value <0.0001) Table 1. HsCRP level was 
1.79 (0.01–31.00) μg/mL in non-MetS subjects vs. 2.94 
in MetS subjects (0.01–31.00) μg/mL (P value  <0.0001) 
Table 1.
Comparing the Least Square Means (LSMeans) 
between non-MetS and MetS subjects showed sig-
nificant increase in the level of ANGPTL8 in the 
MetS subjects as shown in Fig.  1a (P value  =  0.032). 
Dividing the population according to the number of 
MetS components showed increased ANGPTL8 level 
as the number of MetS components increases Fig. 1b (P 
value <0.0001).
Partial Spearman’s correlation adjusted for gender 
and ethnicity showed that ANGPTL8 was positively 
correlated to HsCRP level (r = 0.15, P < 0.001) Table 2. 
ANGPTL8 also showed strong positive correlation to age 
(r =  0.59, P  <  0.001), BMI (r =  0.16, P  <  0.001), waist/
hip ratio (r = 0.32, P < 0.001), FBG (r = 0.43, P < 0.001), 
HbA1c (r  =  0.38, P  <  0.001), HOMA-IR (r  =  0.33, 
P  <  0.001). Similarly using partial Spearman’s analysis 
adjusting for gender and ethnicity HsCRP was positively 
associated with age, BMI, waist/hip ratio, FBG, HbA1c 
and HOMA-IR as shown in Table 2.
In order to understand the association between 
ANGPTL8 and HsCRP, the population was divided 
according to tertiles of HsCRP. Age and ethnicity 
adjusted estimates of ANGPTL8 means showed signifi-
cant association between levels of ANGPTL8 and HsCRP 
among all subgroups. Overall, subjects in the highest ter-
tiles of HsCRP had the highest ANGPTL8 levels Fig. 2a. 
Dividing the population according to MetS, both subjects 
in the MetS and non-MetS groups showed a similar trend 
where subjects in the highest tertile of HsCRP had the 
highest level of ANGPTL8 Fig. 2b, c.
In order to understand the effect of obesity on the 
association between the ANGPTL8 and HsCRP, the 
Table 1 Clinical and biochemical profile for study subjects
Results are reported as Mean ± SD except for non‑normally distributed 
ANGPTL8 and HsCRP that are presented as median (range)
Variable Control N = 724 MetS N = 1011 P value
Age (years) 41.1 ± 10.6 49.0 ± 10.9 <0.0001
Height (m) 1.64 ± 0.09 1.65 ± 0.09 0.0723
Weight (kg) 74.4 ± 16.3 84.9 ± 17.1 <0.0001
BMI (kg/m2) 27.6 ± 5.3 31.3 ± 6.02 <0.0001
Waist (cm) 91.6 ± 12.7 101.8 ± 12.4 <0.0001
Hip (cm) 102.3 ± 11.5 108.8 ± 12.3 <0.0001
Wc/hip ratio 0.90 ± 0.08 0.94 ± 0.08 <0.0001
Systolic (mmHg) 123.7 ± 17.4 137.7 ± 18.7 <0.0001
Diastolic (mmHg) 75.6 ± 10.6 82.6 ± 11.8 <0.0001
FBG (mmol/L) 5.39 ± 1.92 7.05 ± 2.9 <0.0001
Hba1c (%) 5.71 ± 1.15 6.85 ± 1.9 <0.0001
Insulin μU/mL 8.31 ± 13.6 13.56 ± 18.3 <0.0001
HOMAIR 2.13 ± 5.70 4.52 ± 2.70 <0.0001
TC (mmol/L) 5.05 ± 1.03 5.14 ± 1.12 0.0683
TG (mmol/L) 1.18 ± 0.61 1.86 ± 1.22 <0.0001
HDL (mmol/L) 1.27 ± 0.35 1.05 ± 0.27 <0.0001
LDL (mmol/L) 3.26 ± 0.93 3.28 ± 0.98 0.7189
ANGPTL8 (pg/ml) 710.5 (59.5–11597.2) 1140.6 (171.9–11736.1) <0.0001
HsCRP (μg/mL) 1.79 (0.01–31.00) 2.94 (0.01–31.00) <0.0001
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population was divided according to BMI into non-
obese and obese subjects. BMI between 18.5 and 29.9 
was considered non-obese, while BMI equal to or 
higher than 30 was considered obese. Weak associa-
tion was observed between ANGPTL8 and HsCRP in 
the non-obese (p value = 0.0524) Fig. 3a. On the other 
hand, in the obese group, a significant association was 
observed and subjects in the highest tertiles of HsCRP 
Fig. 1 Circulating level of ANGPTL8 in subjects MetS. a Least square 
means of plasma level of ANGPTL8 in MetS vs non‑MetS subjects. 
b Least square means of plasma level of ANGPTL8 according to the 
number of MetS components
Table 2 Partial spearman correlation coefficients 
of  ANGPTL8 and  CRP with  various parameters adjusted 
for ethnicity and gender
Markers ANGPTL8 HsCRP
r p value r p value
Age 0.59 <0.0001 0.09 0.0024
BMI 0.16 <0.0001 0.41 <0.0001
WC/HIP ratio 0.32 <0.0001 0.21 <0.0001
FBG 0.43 <0.0001 0.18 <0.0001
Hba1C 0.38 <0.0001 0.22 <0.0001
Insulin 0.19 <0.0001 0.33 <0.0001
HOMAIR 0.33 <0.0001 0.34 <0.0001
HsCRP 0.15 <0.0001 0.15 <0.0001
Fig. 2 Association between ANGPTL8 and HsCRP according to MetS. 
a least square means of circulating level of ANGPTL8 according to 
HsCRP tertiles in all the subjects. b ANGPTL8 level in non‑MetS sub‑
jects according to HsCRP tertiles. c ANGPTL8 level in MetS subjects 
according to HsCRP tertiles. Tertile values of HsCRP are expressed as 
T1 (<1.39 μg/mL), T2 (1.39–4.07 μg/mL), and T3 (>4.07 μg/mL)
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had higher levels of ANGPTL8 (p value  =  <0.0003) 
Fig. 3b.
Multiple logistic regression analysis of ANGPTL8 and 
HsCRP showed that in the unadjusted model, subjects 
in the highest tertile of ANGPTL8 were more likely to 
have MetS (OR = 4.4, 95 % CI = 3.4–5.7) Table 3. After 
adjustment for age, gender and ethnicity in Model-2, sub-
jects in the highest tertile of ANGPTL8 had higher odds 
of having MetS (OR = 2.8, 95 % CI = 2.0–3.9). Further 
adjustment for HsCRP in Model-3 did not affect the 
association and subjects in the highest tertile still had 
higher odds of having MetS (OR = 2.4, 95 % CI = 1.6–
3.6) (P trend <0.0001). Multiple logistic regression anal-
ysis for HsCRP showed that in the unadjusted model, 
subjects in the highest tertile of HsCRP were more likely 
to have MetS (OR = 2.4, 95 % CI = 1.8–3.1) Table 3. Fur-
ther adjustment for age, gender and ethnicity in Model-2 
and HsCRP in Model-3 did not affect the association and 
subjects in the highest tertile in model-3 still had higher 
odds of having MetS (OR =  2.3, 95  % CI =  1.6–3.1) (P 
trend <0.0001) Table 3.
Discussion
In this study we showed that ANGPTL8 circulation level 
was higher in subject with MetS as well as subjects with 
increasing number of MetS components such as insulin 
resistance and central obesity. ANGPTL8 showed sig-
nificant association with HsCRP where both showed 
significant positive association with BMI, TG, LDL, 
HOMA-IR and FBG. Age and ethnicity adjusted esti-
mates of ANGPTL8 were increased in concordance with 
HsCRP level in subjects with MetS or without as well as 
across different BMI groups. Finally, higher ANGPTL8 
levels were associated with 2.4-fold increase in the odds 
of having MetS. Higher HsCRP levels on the other hand 
were associated with a 2.3-fold increase in the odds of 
having MetS. Taken together, our data clearly indicate 
that increased ANGPTL8 level is associated with higher 
level of HsCRP and incidence of MetS in our population.
ANGPTL protein family members have been shown 
to play a major role in obesity and metabolic diseases 
[26–29]. ANGPTL3 and 4 have been heavily involved in 
lipid metabolism through their regulation of lipoprotein 
lipase (LPL) activity [26]. ANGPTL8 has been recently 
Fig. 3 Association between ANGPTL8 and HsCRP according to 
obesity. a least square means of circulating level of ANGPTL8 accord‑
ing to HsCRP tertiles in non‑obese subjects. b ANGPTL8 level in 
obese subjects according to HsCRP tertiles. Tertile values of HsCRP 
are expressed as T1 (<1.39 μg/mL), T2 (1.39–4.07 μg/mL), and T3 
(>4.07 μg/mL). BMI between 18.5–29.9 was considered non‑obese 
while BMI equal to or higher than 30, was considered obese
Table 3 OR (95 % CI) by multiple logistic regression models for metabolic syndrome in relation to ANGPTL8 and HsCRP
Model 1 unadjusted; Model 2 adjusted for age, gender and ethnicity; Model 3 adjusted for ANGPTL8 + CRP + Model 2. Tertile values of HsCRP are expressed as T1 
(<1.39 μg/mL), T2 (1.39–4.07 μg/mL), and T3 (>4.07 μg/mL). Tertile values of ANGPTL8 are T1 (<689.52 pg/ml), T2 (689.52–1302.63 pg/ml), and T3 (>1302.63 pg/ml)
Models T1 T2 95 % CI T3 95 % CI P trend
ANGPTL8
 Model 1 1 2.3 (1.8–2.8) 4.4 (3.4–5.7) <0.0001
 Model 2 1 1.7 (1.3–2.2) 2.8 (2.0–3.9) <0.0001
 Model 3 1 1.7 (1.2–2.3) 2.4 (1.6–3.6) <0.0001
HsCRP
 Model 1 1 2.0 (1.5–2.7) 2.4 (1.8–3.1) <0.0001
 Model 2 1 1.8 (1.3–2.5) 2.5 (1.8–3.4) <0.0001
 Model 3 1 1.8 (1.3–2.4) 2.3 (1.6–3.1) <0.0001
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recognized as another member of this family that plays 
a role in lipid metabolism and insulin signalling [14, 15, 
17, 21, 22, 30]. It has been shown to regulate LPL activity 
through its interaction with ANGPTL3 [15]. It has also 
been found that an arginine (R) to tryptophan (W) R59W 
sequence variant in the ANGPTL8 gene has been associ-
ated with lower LDL-C and HDL-C in some ethnicities 
[15]. Its overexpression leads to increased TG in serum 
while its knockout has led to increased LPL activity and 
reduced fatty acid uptake by adipose tissues [30]. It has 
also been shown to play a role in insulin signalling and has 
been initially suggested to increase beta-cell proliferation 
[13]. However, recent studies found that ANGPTL8 had no 
effect on beta cell growth in mice, thus raising questions 
on how ANGPTL8 improves glucose tolerance [19, 20]. 
We and others have recently showed that ANGPTL8 level 
was increased in T2D [21, 31–33] and its level associated 
with FBG and insulin resistance in a large human cohort 
[21]. We also showed that it was associated with C-peptide 
production in non-diabetic subjects [22]. In this study we 
further show that ANGPTL8 is increased in MetS and is 
associated with HsCRP. Our current data is in line with 
what has been reported about the increased ANGPTL8 
level in obesity and T2D [21, 31–34]. Other studies 
showed that ANGPTL8 was reduced in T2D [35, 36]. 
MetS is recognized as a cluster of metabolic risk factors 
including central obesity and insulin resistance [23, 37–
39]. Based on its involvement in two key pathways (lipid 
metabolism and insulin resistance), we hypothesized that 
the increased ANGPTL8 level caused by insulin resistance 
in MetS subjects will lead to an increased release of TG 
into plasma. This may be done through its ability to regu-
late the cleavage of active ANGPTL3 that leads to inhibi-
tion of LPL enzyme activity [15]. Cleavage of ANGPTL3 
causes the release of its N-terminal domain that can act 
as a potent inhibitor of LPL activity [15]. Even though 
this might be a plausible analysis, a follow up study will 
be necessary to establish causality highlighting one of the 
limitations of the current study due to its cross-sectional 
nature. On the other hand, one of the strengths of this 
study is the large sample size used as well as the population 
being studied, which has not been well studied yet and is 
being recognized as a high risk population particularly the 
South Asians. It important to note that the EIAAB ELISA 
used in this study recognizes ANGPTL8 at its N-terminus 
and measures the full length form. The C-terminal form 
of ANGPTL8 is measured using Phoenix Pharmaceuti-
cals ELISA kit that reacts with C-terminus and measures 
truncated ANGPTL8 [40, 41]. We have recently showed 
that both forms show a similar trend in obesity and their 
level was reduced after exercise, however, only full length 
ANGPTL8 showed association with FBG [40].
HsCRP has been shown to closely associate with MetS 
and acts as a marker for low grade systemic inflamma-
tion [38]. Its addition to MetS definition has been sug-
gested to increase its predictive power of CVD and T2D 
[9–12]. To gain better understanding on the function 
of ANGPTL8 in MetS we looked at its association with 
HsCRP as a marker of inflammation. This is because 
it has been suggested that the disease progression in 
subjects with MetS towards T2D is accompanied by 
increased inflammation [42]. Our data shows positive 
correlation between ANGPTL8 and HsCRP suggesting 
that the inflammatory process might be connected to 
the increase in ANGPTL8 in humans that could result 
in aggravated dyslipidemia. Similarly, ANGPTL3 and 4 
have previously showed positive association with MetS 
[43] and ANGPTL4 showed positive association with 
CRP [42]. The close association between the ANGPTL8 
and HsCRP shows that ANGPTL8 may be used in the 
future as a predictor of MetS and possibly CVD in com-
bination with HsCRP.
In conclusion, our data shows that circulating 
ANGPTL8 level is increased in subjects with MetS or 
some of its components and this increase coincide with 
increase in the HsCRP level where both proteins can act 
as independent predictors of MetS. This data highlights 
the potential role of ANGPTL8 in MetS and the potential 
usage of this molecule as a predictive biomarker for MetS 
and CVD in the future.
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